Selective ophthalmic intra-arterial melphalan therapy for advanced retinoblastoma: Implementation and outcomes of a new chemotherapy protocol

Journal of Oncology Pharmacy Practice

Volumn 19, Issue 2, 2013, Pages 159-164

  García, Silvia Valero ^a   Briz, Eduardo López ^a   Cava, Paloma Escobar ^a   Balaguer, Julia ^a   Pelufo, Ana ^b   Megías, Juan Eduardo ^a   Andrés, Jose Luis Poveda ^a  

^a H La Fe   (Spain)

^b HOSPITAL LLUÍS ALCANYÍS   (Spain)

Author keywords

melphalan; ophthalmic; Retinoblastoma

Indexed keywords

MELPHALAN;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CLINICAL ARTICLE; DISEASE COURSE; GROUPS BY AGE; HUMAN; INFANT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACIST; PRACTICE GUIDELINE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETINOBLASTOMA;

MELPHALAN; OPHTHALMIC; RETINOBLASTOMA;

ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD, PRESCHOOL; COOPERATIVE BEHAVIOR; FEMALE; HUMANS; INFANT; INFUSIONS, INTRA-ARTERIAL; MALE; MELPHALAN; OPHTHALMIC ARTERY; PATIENT CARE TEAM; PHARMACISTS; PHARMACY SERVICE, HOSPITAL; PROFESSIONAL ROLE; RETINAL NEOPLASMS; RETINOBLASTOMA; TREATMENT OUTCOME;

EID: 84879311260     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155212457964     Document Type: Article

References (24)

1. Kaufman PL, Teed RGW UpToDate. Basow DS, ed. Waltham, MA: UpToDate ; 2011 :
2. Reese AB, Ellsworth RM. Evaluation and current concept in retinoblastoma therapy. Trans Am Acad Ophthlalmol Otolaryngol. 1963 ; 67: 164-172
3. Gao YJ, Qian J, Yue H, et al. Clinical characteristics and treatment outcome of children with intraocular retinoblastoma: a report from a Chinese cooperative group. Pediatr Blood Cancer. 2011 ; 57 (7). 1113-1116
4. Sastre X, Chantada GL, Doz F, et al. Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch Pathol Lab Med. 2009 ; 133 (8). 1199-1202
5. Lin P, O'Brien JM. Frontiers in the management of retinoblastoma. Am J Ophthalmol. 2009 ; 148 (2). 192-198
6. Shields CL, Meadows AT, Leahey AM, et al. Continuing challenges in the management of retinoblastoma with chemotherapy. Retina. 2004 ; 24 (6). 849-862
7. Suzuki S, Yamane T, Mohri M, et al. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology. 2011 ; 118 (10). 2081-2087
8. McDaid C, Hartley S, Bagnall A-M, et al. Systematic review of effectiveness of different treatments for childhood retinoblastoma. Health Technol Assess 2005; 9(48): iii, ix-x, 1-145..
9. Vajzovic LM, Murray TG, Aziz-Sultan MA, et al. Supraselective intra-arterial chemotherapy: evaluation of treatment-related complications in advanced retinoblastoma. Clin Ophthalmol. 2011 ; 5: 171-176
10. Inomata M, Kaneko A. Chemosensitivity profiles of primary and cultured human retinoblastoma cells in a human tumor clonogenic assay. Jpn J Cancer Res. 1987 ; 78 (8). 858-868
11. Abramson DH, Dunkel IJ, Brodie SE, et al. Bilateral superselective ophthalmic artery chemotherapy for bilateral retinoblastoma: tandem therapy. Arch Ophthalmol. 2010 ; 128 (3). 370-372
12. Vajzovic LM, Murray TG, Aziz-Sultan MA, et al. Clinicopathologic review of enucleated eyes after intra-arterial chemotherapy with melphalan for advanced retinoblastoma. Arch Ophthalmol. 2010 ; 128 (12). 1619-1623
13. Ohshima K, Kaneko T, Takagi S, et al. Clinicopathological investigation of a retinoblastoma eye enucleated after vitreous surgery with melphalan perfusion. Jpn J Ophthalmol. 2009 ; 53 (2). 186-188
14. Gobin YP, Dunkel IJ, Marr BP, et al. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 2011 ; 129 (6). 732-737
15. Brodie SE, Pierre Gobin Y, Dunkel IJ, et al. Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma. Doc Ophthalmol. 2009 ; 119 (1). 13-22
16. Peterson EC, Elhammady MS, Quintero-Wolfe S, et al. Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors. J Neurosurg. 2011 ; 114 (6). 1603-1608
17. Aziz HA, Boutrid H, Murray TG, et al. Supraselective injection of intraarterial melphalan as the primary treatment for late presentation unilateral multifocal stage Vb retinoblastoma. Retina. 2010 ; 30 (4 Suppl). S63 - S65
18. Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. Int J Clin Oncol. 2004 ; 9 (2). 69-73
19. Product information: melphalan HCl injection, melphalan HCl injection. Lake Forest, IL: Bioniche Pharma USA LLC ; 2008 :
20. Pinguet F, Martel P, Rouanet P, et al. Effect of sodium chloride concentration and temperature on melphalan stability during storage and use. Am J Hosp Pharm. 1994 ; 51: 2701-2704
21. Beitz C, Bertsch T, Hannak D, et al. Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials. Int J Pharm. 1999 ; 185: 113-121
22. Marr B, Gobin PY, Dunkel IJ, et al. Spontaneously resolving periocular erythema and ciliary madarosis following intra-arterial chemotherapy for retinoblastoma. Middle East Afr J Ophthalmol. 2010 ; 17 (3). 207-209
23. Venturi C, Bracco S, Cerase A, et al. Superselective ophthalmic artery infusion of melphalan for intraocular retinoblastoma: preliminary results from 140 treatments. Acta Ophthalmol 2012. Epub ahead of print. DOI: 10.1111/j.1755-3768.2011.02296.x.
24. Howarth C, Meyer D, Hustu HO, et al. Stage-related combined modality treatment of retinoblastoma: results of a prospective study. Cancer. 1980 ; 45 (5). 851-858